Equity Overview
Price & Market Data
Price: $5.54
Daily Change: +$0.07 / 1.26%
Daily Range: $5.35 - $5.69
Market Cap: $380,865,152
Daily Volume: 180,146
Performance Metrics
1 Week: -2.44%
1 Month: 17.31%
3 Months: 197.4%
6 Months: 294.4%
1 Year: 7.77%
YTD: 46.72%
Company Details
Employees: 81
Sector: Health technology
Industry: Biotechnology
Country:
Details
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. Its lead product candidates comprise PGN-EDO51, an EDO peptide which is Phase 2 clinical trial to treat duchenne muscular dystrophy (DMD) patients that are amenable to an exon 51-skipping approach; PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and PGN-EDO53, which is in preclinical trial to treat duchenne muscular dystrophy. The company was founded in 2018 and is based in Boston, Massachusetts.